IL276777B1 - Preparations for the treatment of wet age-related macular degeneration - Google Patents

Preparations for the treatment of wet age-related macular degeneration

Info

Publication number
IL276777B1
IL276777B1 IL276777A IL27677720A IL276777B1 IL 276777 B1 IL276777 B1 IL 276777B1 IL 276777 A IL276777 A IL 276777A IL 27677720 A IL27677720 A IL 27677720A IL 276777 B1 IL276777 B1 IL 276777B1
Authority
IL
Israel
Prior art keywords
compositions
treatment
macular degeneration
related macular
wet age
Prior art date
Application number
IL276777A
Other languages
English (en)
Hebrew (he)
Other versions
IL276777A (en
Original Assignee
Univ Pennsylvania
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Regenxbio Inc filed Critical Univ Pennsylvania
Publication of IL276777A publication Critical patent/IL276777A/en
Publication of IL276777B1 publication Critical patent/IL276777B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL276777A 2018-02-20 2020-08-18 Preparations for the treatment of wet age-related macular degeneration IL276777B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632775P 2018-02-20 2018-02-20
US201862663532P 2018-04-27 2018-04-27
PCT/US2019/018640 WO2019164854A1 (en) 2018-02-20 2019-02-19 Compositions for treatment of wet age-related macular degeneration

Publications (2)

Publication Number Publication Date
IL276777A IL276777A (en) 2020-10-29
IL276777B1 true IL276777B1 (en) 2025-12-01

Family

ID=67688300

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276777A IL276777B1 (en) 2018-02-20 2020-08-18 Preparations for the treatment of wet age-related macular degeneration

Country Status (10)

Country Link
US (1) US20210093734A1 (enExample)
EP (1) EP3755804A4 (enExample)
JP (2) JP2021516671A (enExample)
KR (1) KR20210022524A (enExample)
AU (2) AU2019223963A1 (enExample)
CA (1) CA3090293A1 (enExample)
IL (1) IL276777B1 (enExample)
MA (1) MA51916A (enExample)
SG (1) SG11202007252VA (enExample)
WO (1) WO2019164854A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568774A1 (en) * 2017-01-12 2019-11-20 Telefonaktiebolaget LM Ericsson (PUBL) Anomaly detection of media event sequences
KR20200060456A (ko) * 2017-09-27 2020-05-29 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항-VEGF Fab를 이용한 안구 질환의 치료
JP2021506861A (ja) 2017-12-19 2021-02-22 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
US11360969B2 (en) * 2019-03-20 2022-06-14 Promethium, Inc. Natural language based processing of data stored across heterogeneous data sources
WO2021046245A1 (en) * 2019-09-04 2021-03-11 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
US20230139443A1 (en) * 2020-02-28 2023-05-04 The Trustees Of The University Of Pennsylvania Treating autosomal dominant bestrophinopathies and methods for evaluating same
US20230152336A1 (en) * 2020-04-24 2023-05-18 Siemens Healthcare Diagnostics Inc. Calibration and quality control reagents for use with immunoassays for antibodies and methods of production and use thereof
WO2021255590A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
WO2021255589A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
AU2021362770A1 (en) 2020-10-16 2022-12-08 Gyroscope Therapeutics Limited Nucleic acid encoding an anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
KR102789747B1 (ko) * 2021-12-29 2025-04-03 한국과학기술원 Prox1 단백질에 중화 활성을 갖는 결합 분자
AU2023215253A1 (en) * 2022-02-02 2024-09-19 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
WO2017180936A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120622A1 (es) * 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
WO2017180936A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration

Also Published As

Publication number Publication date
MA51916A (fr) 2021-05-26
SG11202007252VA (en) 2020-09-29
EP3755804A1 (en) 2020-12-30
AU2019223963A1 (en) 2020-08-13
KR20210022524A (ko) 2021-03-03
WO2019164854A1 (en) 2019-08-29
US20210093734A1 (en) 2021-04-01
JP2024016207A (ja) 2024-02-06
IL276777A (en) 2020-10-29
AU2025204780A1 (en) 2025-07-17
CA3090293A1 (en) 2019-08-29
EP3755804A4 (en) 2021-12-15
JP2021516671A (ja) 2021-07-08

Similar Documents

Publication Publication Date Title
IL276777A (en) Preparations for the treatment of macular degeneration associated with wet age
SG10201913159UA (en) Compositions for treatment of wet age-related macular degeneration
IL269378A (en) Optimal antibody preparations for the treatment of ocular disorders
IL287843A (en) Triaryl compounds for the treatment of pd-l1 diseases
EP3373972C0 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
PL3399962T3 (pl) Kompozycja okulistyczna do leczenia choroby suchego oka
EP3697920A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
IL267146A (en) A method for treating macular degeneration
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
ZA201904660B (en) Treatment of aqueous compositions including fines
EP3160460A4 (en) Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
LT3573620T (lt) Kompozicijos, skirtos hipertenzijos gydymui
EP3886852A4 (en) Method of treating age-related macular degeneration
GB201612043D0 (en) Composition for treatment of disorders
EP3672579A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHICAL ATROPHY
ZA201904051B (en) Peptide for treating age-related macular degeneration
ZA201907238B (en) Compositions for treating neurodegenerative diseases
PL3746114T3 (pl) Kompozycje do zastosowania w leczeniu zaćmy
GB201616158D0 (en) Age-related macular degeneration
KR102384118B9 (ko) 황반변성 예방 또는 치료용 조성물
EP3849596C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
GB201806663D0 (en) 2-Oxothiazole compositions for treatment of fibrotic disease
SI3519050T1 (sl) Sestavki za zdravljenje očesnih obolenj
IL252543B (en) Compounds for the treatment of degenerative retinal tissues
HK40043288A (en) Compositions for treatment of wet age-related macular degeneration